Leak, Cerebrospinal Fluid
Conditions
Brief summary
To collect post-approval data comparing the safety and effectiveness of CraniSeal Dural Sealant to DuraSeal Dural Sealant. The study has been powered specifically to determine whether the CraniSeal device when used as an adjunct to sutured dural closure following elective cranial surgery is no worse than (i.e., non-inferior) to the DuraSeal device with respect to proportion of subjects free from post-operative cerebrospinal fluid (CSF) leaks. Additional safety outcomes (i.e., surgical site infections and adverse events/device-related adverse events) will also be captured and compared.
Interventions
DEVICECraniSeal
CraniSeal is a PEG Dural Sealant
DEVICEDuraSeal
DuraSeal is a PEG Dural Sealant
Sponsors
Pramand LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Masking description
Participant will be blinded to dural sealant until they have completed 90 day study.
Intervention model description
Randomized 1:1 CraniSeal vs Comparator
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
General Inclusion Criteria: 1. Patient is ≥ 18 years of age 2. Patient is scheduled for an elective infratentorial or supratentorial cranial procedure under general anesthesia that entails a dural incision 3. Patient requires a procedure involving surgical wound classification Class I/Clean 4. Patient signs a written Informed Consent form to participate in the study, prior to any study mandated determinations or procedures. 5. Patients who are able to comply with study requirements. General
Exclusion criteria
1. Patient requires a procedure involving translabyrinthine, transsphenoidal, transoral and/ or any procedure that penetrates the air sinus or mastoid air cells; superficial penetration of air cells are not excluded 2. Patient has had a prior intracranial neurosurgical procedure in the same anatomical location 3. Patient with diagnosis of severely altered renal (creatinine levels \> 2.0 mg/dL) or hepatic (total bilirubin \> 2.5 mg/dL) function 4. Patient diagnosed with a compromised immune system or autoimmune disease (WBC count less than 4000/uL or greater than 20,000/uL) 5. Patients undergoing cranial procedures involving petrous bone drilling 6. Patients with traumatic injuries to the head or dural disease in planned dural closure area 7. Patients who are pregnant or lactating 8. Patient with an active infection 9. Patient is undergoing cranial procedures involving non-autologous duraplasty material that are not collagen based 10. Patients requiring re-opening of planned surgical area within 90 days after surgery. 11. Patient with a known allergy to FD\&C Blue #1 dye 12. Patient is not able to tolerate multiple Valsalva maneuvers, or transient elevation of CSF pressure during Valsalva maneuvers is not possible (e.g. the presence of a temporary or permanent CSF shunt 13. Presence of hydrocephalus 14. Patient with a diagnosis of uncontrolled diabetes (e.g., persistent HbA1c elevation of \>9% despite standard diabetes care), 15. Patient has a documented, uncorrectable clinically significant coagulopathy (e.g., PTT\>37 seconds or INR \>1.5 units) 16. Patient is not likely to comply with the follow-up evaluation schedule. 17. Contraindications to both an MRI and CT scan. 18. Patients participating in any investigational device study within 30 days or currently receiving an investigational drug/biologic therapy. (Observational studies on FDA approved products are not applicable) 19. Patients diagnosed with Meningiomatosis (multiple meningiomas)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Absence of CSF Leaks | 90 days | absence of CSF leaks on study |
Countries
United States
Contacts
CONTACTM Pace
Outcome results
None listed